---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-034551"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:57:41.028579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Connect licensee Simcere submits NDA for rademikibart in China for atopic dermatitis

## Summary
- Simcere submitted NDA to NMPA for rademikibart to treat atopic dermatitis in adults and adolescents.
- Connect eligible for up to $110M in remaining development, regulatory, and commercial milestone payments.
- Connect also eligible for tiered royalties up to low double-digit percentages on Greater China net sales.
- Rademikibart is a next-generation IL-4Rα antibody; AD market in China estimated at 70M patients.
- Connect retains all rights outside Greater China under the 2023 license agreement with Simcere.

## SEC filing metadata
- accession: 0001628280-25-034551
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000162828025034551/0001628280-25-034551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000162828025034551/cntb-20250709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-034551
- JSON: https://secwatch.observer/filing/0001628280-25-034551.json
- Plain text: https://secwatch.observer/filing/0001628280-25-034551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.